Company intelligence / Profile preview

Jilin Sanjiu Jin Fu Kang Pharmaceutical

Yanbian Chaoxian Autonomous Prefecture / General reference to "Jilin", Jilin Sheng (Province), Chinapitchbook.com ↗

Ownership: Private
Development stage: Other

Overview

Jilin Sanjiu Jin Fu Kang Pharmaceutical focuses on the development and commercialization of herbal medicines. Its flagship product, "Jinfukang," is an oral liquid herbal formulation approved in China for the treatment of lung cancer since March 2020. There are no publicly available detailed clinical results or additional pipeline programs reported as of June 2025[2][4].

Therapeutic areas: Oncology
Modalities: Herbal medicine
Industry: Biotech

Beyond the preview

Go deeper on Jilin Sanjiu Jin Fu Kang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jilin Sanjiu Jin Fu Kang Pharmaceutical.

Explore the full profile